UNSPSC 85819403: Transfusion of autologous cord blood stem cells into peripheral vein, open approach

This classification denotes the group of activities that yields a surgical intervention or procedure to transfusion of autologous cord blood stem cells into peripheral vein, open approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 30230X0

UNSPSC 85819403 Transfusion of autologous cord blood stem cells into peripheral vein, open approach is a Commodity code that shows no recent state and local procurement activity aligned with its nominal scope. The six most-recent opportunities posted under this code between July and September 2026 solicit independent medical evaluation services for public safety pension disability determinations (Phoenix); surgical procedure carve-out benefits for municipal employees (Long Beach); occupational medical surveillance for state ferry workers (Washington); emergency and specialty hospital services for detained youth (Harris County); pharmacy benefit management (Collier County); and temporary health professional staffing across clinical categories including audiology, cardiology, radiology, gastroenterology, and therapy services (Santa Clara County Health System). None of these solicitations involve cord blood stem cell transfusion, regenerative medicine, hematology specialty care, or related clinical or laboratory services. The code appears to be misapplied to a broad range of occupational health, benefits administration, and temporary staffing vehicles that do not match the code's specific medical procedure definition.

The issuing bodies span state health authorities, county governments, municipalities, and special-purpose health districts across Arizona, California, Florida, and Washington. With no recent opportunities actually aligned to cord blood stem cell transfusion procurement, this code presents minimal market signal for business development focused on the specific clinical service it nominally describes. Firms offering stem cell collection, processing, banking, or transfusion services should treat this code as dormant for state and local opportunity capture and instead monitor codes addressing cellular therapy procurement, tissue engineering services, or regenerative medicine more broadly if available in the UNSPSC taxonomy.